Vyxeos® is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

For full details please refer to the PI as approved by the IL MoH.

BLINCYTO® is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.

BLINCYTO® is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

BLINCYTO® is indicated as monotherapy for the treatment of pediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy.

BLINCYTO® is indicated as monotherapy for the treatment of pediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.

For full details please refer to the PI as approved by the IL MoH.
Limitations of use: After failure of two previous treatments and with no CNS involvement.
License Holder: Amgen Europe B.V., Israel Branch.

ICLUSIG® is indicated in adult patients with: chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML)* who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

* Clarification regarding CML treatment: If the patient received dasatinib/ nilotinib as the first line of therapy and failed, he can receive Iclusigin the second line. If the patient received Imatinib in the first line and failed and received dasatinib/ nilotinib in the second line and failed, he can receive Iclusigas the third line of therapy.

ICLUSIG® is indicated in adult patients with: Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
For full details please refer to the PI as approved by the IL MoH. ICLUSIG and the ICLUSIG logo are registered trademarks of ARIAD Pharmaceuticals, Inc.